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MRIAbstract Magnetic resonance imaging is the only tool, that provides the possibility of studying
bone marrow edema.
Aim of the work: To investigate whether DCE-MRI has a role in assessing disease activity in RA.
Furthermore, if these imaging parameters could provide reliable information about destructive joint
changes during follow up period.
Patients and methods: 48 Patients with early RA were followed up with plain X-ray of both hands
and feet with DCE-MRI of the clinically more affected wrist. Synovial inﬂammation was assessed
by measuring E-rate. Synovial membrane hypertrophy, bone edema and erosions were scored by
OMERACT at baseline and 18 months. Response to treatment was evaluated based on whether
or not P50% improvement was achieved.
Results: Erosion score progressed while clinical and laboratory measures improved signiﬁcantly
from baseline to 18 months. Baseline bone edema, synovitis, pain scores, E-rate and ESR were cor-
related with static MRI erosion score at 18 months.
Conclusion: DCE-MRI produces sensitive information regarding diagnosing and scoring synovitis
(1–3) in early RA. Furthermore, it provides studying bone marrow edema which is the strongest
predictor of bone erosion in early RA. Hence we conclude that DCE-MRI has a diagnostic and
prognostic value in predicting bone erosion development later on.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
Early rheumatoid arthritis (RA) is characterized by synovitis,
inﬂammation and hypertrophy of synovial membrane tissue,
which is presumably associated with subsequent cartilage
destruction and bone erosion (1). The central importance of
joint remodeling processes in RA pathology is highlighted by
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ing techniques is a major diagnostic, monitoring, and outcome
parameter in both clinical trials and routine clinical practice
(2). Structural joint damage, a major outcome in rheumatoid
arthritis (RA), has traditionally been measured by scoring
methods applied to radiological images. However, only the late
signs of preceding disease activity can be visualized by radiog-
raphy. Magnetic resonance imaging (MRI) can detect RA ero-
sive changes with greater sensitivity than conventional
radiography, particularly in early disease. In addition, MRI
allows direct visualization and assessment of synovitis, the
primary lesion in RA, and of bone edema, a ﬁnding unique
to MRI and a probable forerunner of bone erosions (3).
Studies on very early arthritis (63 months from symptom
onset) have shown that up to 20% of RA patients already
present with erosions at baseline despite early referral, and
substantial structural damage further develops even during dis-
ease-modifying anti rheumatic drug (DMARD) therapy (4).
On the other hand, rheumatologist in daily clinical practice
well appreciate that a considerable number of patients does
not experience any erosion even after long-term disease.
Following the greater availability of treatment targets and
options, the prospect of distinguishing which patient with early
RA is to run a severe disease course and which is not, at
present, is one of the main challenges in the management of
RA (4).
DCE-MRI is a technique based on the sequential acquisi-
tion of rapid MRI sequences before and during the infusion
of a contrast agent. It has previously been used to evaluate
synovial inﬂammatory activity in patients with RA in the
knees showing that the steepness of the dynamic curves corre-
lates better with histological synovial vascularity and inﬂam-
matory cell inﬁltrate than measures of the corresponding
post-contrast-enhancing synovial volumes (5). E-rate indicat-
ing the speed and intensity of the diffusion of contrast agent
in inﬂamed tissue can be calculated from these images. The
early enhancement rate has been shown to tolerate the num-
ber, size and permeability of synovial vessels as well as to
the volume of the synovial membrane (6). DCE-MRI poten-
tially allows detection of the early change in perfusion and
inﬂammation upon treatment, which seems to occur before
change in synovial volume and BME is seen in conventional
MRIs (7). The main objective of this study was to investigate
whether dynamic contrast enhanced-magnetic resonance imag-
ing (DCE-MRI) has a role in assessing joint inﬂammation and
disease activity in rheumatoid arthritis (RA). Furthermore, if
these imaging parameters could provide reliable information
about further destructive joint changes during 18 months
follow up period.2. Patients and methods
Forty-eight patients with early Rheumatoid Arthritis RA
(disease duration less than 1 year) fulﬁlling the revised Ameri-
can College of Rheumatology criteria of RA (8) plain X-ray of
both hands and feet (modiﬁed Sharp score) (9), contrast
enhanced MRI of the clinically more affected wrist, laboratory
and clinical assessment at baseline and 18 months follow up
period. Details of MRI parameters, clinical measures and med-
ications are present in (Table 1). All patients were recruitedfrom out patient clinic of Physical Medicine, Rheumatology
and Rehabilitation Department of Tanta University Hospitals.
Patients were 40 females and 8 males, with a mean age of
45 years. The mean duration of symptoms was 5 months.
Response to treatment at follow up was deﬁned as P50%
improvement in the tender and swollen joint scores, HAQ
score and normal ESR or CRP. At 18 months follow up, all
patients were taking one or more disease modifying anti rheu-
matic drugs (DMARDs), but, anti-tumor necrosis factor alpha
agents were not used by any of the patients.
2.1. Dynamic MRI scans
Imaging of clinically more affected wrist was done using high
ﬁeld strength 1.5 Tesla MRI scanner (Siemens MAGNETOM
ESSENZA). Dynamic scans were obtained in the coronal
plane using a 3D gradient – echo technique. The scans were
localized using the initial axial spin echo localizing sequence.
The continuous slices were arranged to cover all carpal bones.
The imaging parameters were: 30 ms, TE 10 ms, ﬂip angle 40
matrix size 128 · 256, slice thickness 2 mm, ﬁeld of view
160 · 160 cm. Each acquisition consists of 12 slices and was
obtained in 59 s. A pre-contrast scan was performed, then a
15 ml of Gd DTPA bolus (Magnevist 469 mg/ml, Schering
AG) was injected i.v. through a cannula in the opposite fore-
arm. This injection was given over a period of 15–25 s with a
subsequent ﬂush of 10 ml of normal saline, followed by the
ﬁrst post contrast sequence. Five post contrast sequences were
obtained, each of 59 s duration with a delay of 1 s between
them. The imaging time of the dynamic scan was 6 min. Before
contrast – enhanced dynamic imaging, the following sequences
were obtained: STIR SE coronal sequence {1800/25/
80 ms(TR/TE/TI), 18 · 18 cm ﬁeld of view, 216 · 256 matrix,
one excitation slice thickness 3 mm imaging time 9 min 43 s},
T2 FSE axial sequence {4000/100 ms (TR/TE),15 · 15 ﬁeld
of view,240 · 256 matrix, slice thickness 3 mm,0,5 mm gap,
imaging time 6 min}and T1-weighted 3D GRE coronal
sequence {30/10 ms (TR/TE), ﬂip angle 40 16 · 16 cm ﬁeld
of view, 256 · 256 matrix, one excitation, slice thickness
2 mm, imaging time 6 min 9 s}. After dynamic imaging, post
contrast coronal T1-weighted 3D GRE images were obtained.
Total imaging time was about 40 min .
2.2. Assessment of dynamic MRI scans
Analysis of the dynamic data was performed using high ﬁeld
strength 1.5 Tesla MRI scanner (Siemens MAGNETOM ESS-
ENZA). Region of interest (ROI) circle (5–25 mm) was placed
over the region of maximal synovial enhancement within the
carpus. A curve was obtained, plotting the mean pixel intensity
of the ROI circle against the time following the gadolinium
injection. The curve was typically s-shaped (Fig. 1). The rate
of enhancement per second after the ﬁrst post-contrast
sequence (59 s) was calculated as follows: E-rate = SIı – SI/
59 s where SI is the signal intensity before the contrast injec-
tion, and SIı-is the signal intensity reached after completing the
ﬁrst post-contrast sequence (59 s). The highest E-rate value of
each wrist was presented as the maximal E-rate (E-rate max).
An average E-rate value was calculated and presented as the
average E-rate (E-rate average) (see Fig. 2–4).
Table 1 MRI parameters, clinical and laboratory measures and medications at baseline and 18 months follow up.
Baseline(n= 48) 18 months(n= 48) P
MRI data
Erosion score 2(0–4) 5(2–9) <0.05
Synovitis score 5(3–7) 3(2–6.5) >0.05
Edema score 2(0.5–4.5) 0.5(0–2.5) >0.05
E-rate 3.3(1.5–6) 2.8(1.1–4.2) >0.05
Clinical measures
Swollen joint count 14.5(0–38) 2(0–21) <0.05
Tender joint count 13.5(0–37) 5.5(0.25) <0.05
DAS(28) score 5.1(2.7–7.6) 2.8(2.0–5.4) <0.05
HAQ score 0.6(0–1.8) 2(0,8–3) <0.05
ESR (m/st h) 67(25–132) 42(12–85) <0.05
CRP (mq/1) 46(16–55) 18(3–18) <0.05
Pain score 80(40–100) 22(10–50) <0.05
Modiﬁed sharp score 63(48–81) 70(55–97) >0.05
Medication
-DMARD 35(72%) 46(95%)
 Sulphasalazine (1–3 g/day) 3 1
 Methotrexate (7.5–15 mg/week) 8 10
 Hydroxychloroquine 400 mg/day 6 8
 Combination therapy 20 28
-Prednisone (5–10 mg/day) 5(10%) 10(21%)
DAS: disease activity score, HAQ score: health assessment questionnaire score, ESR: erythrocyte sedimentation rate, CRP: C reactive protein.
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Fig. 1 Dynamic MRI shows a steep curve at baseline indicating
intense and rapid enhancement with non-signiﬁcant decrement at
18 months follow up.
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Scoring of synovial hypertrophy, bone edema and bone ero-
sions of the wrist joint was done at baseline and at 18 month
follow-up by reading the STIR images (bone edema) and the
static T1 3D GRE images obtained before and after contrast
enhancement (synovitis and erosions) according to the
Outcome Measures (3) in Rheumatology Clinical Trials
(OMERACT) group RA-MRI Scoring (RAMRIS) system.
Synovitis was scored on a 0–3 scale at three different locations:
radio-ulnar joint, radio-carpal joint and intercarpal–carpo-
metacarpal joints (total maximum score 9). A score of 0 is
normal, with no enhancement or enhancement up to the thick-
ness of normal synovium, while the scores from 1 to 3 (mild,moderate, severe) refer to increments of one-third of the pre-
sumed maximum volume of enhancing tissue in the synovial
compartment. The carpal bones, distal radius, distal ulna
and metacarpal base (15 locations) were scored separately
for bone edema (0–3 based on the volume of edema: 1: 1–
33%; 2: 34–66%;3: 67–100%) and bone erosions (0–10, based
on the proportion of eroded bone compared with ‘‘assessed
bone volume’’: 0: no erosion; 1: 1–10% of bone eroded; 2:
11–20%, etc.). The maximum score for bone edema was 45
and that for bone erosions was 150. The metacarpophalangeal
joints were not evaluated, as they were not completely covered
in the image sets.
Reader was blinded to the clinical and laboratory parame-
ters, and scored the 18 months MRI scans without reference to
the baseline scans. After independent readings, however, an
additional consensus reading was performed with reference
to the baseline scans, to achieve maximum accuracy in scoring
the bone erosions and edema.3. Statistical methods
The association between the baseline parameters and the
change of erosion scores from baseline to 18 months were ana-
lyzed using Spearman’s rank correlation coefﬁcients (R). The
baseline variables that were signiﬁcantly related to erosive pro-
gression, were then incorporated into a multivariate regression
model (forward stepwise). Change in the erosion score of two
or more was chosen as the cut-off value. Friedman’s test was
used to assess the change in the variables over the follow-up.
Mann–Whitney’s U test was used to explore the variable dif-
ferences between the groups obtained based on erosive pro-
gression and the response to treatment. The level of
P< 0.05 was considered statistically signiﬁcant. SPSS 11.0
was used to conduct analyses.
Fig. 2 Serial MRI scans of early RA patient born in 1970. (A) Baseline contrast enhanced coronal T1-weighted MR image shows
intermediate signal intensity consistent with synovitis (B) STIR image shows synovitis as high signal intensity (white arrow). High signal
intensity bone marrow edema appears at the base of the second metacarpal and capitate bones (black arrows). (C) Coronal T2 fat
suppressed MR image at 18 months later shows erosions at sites of previous bone edema at 2nd metacarpal and capitate bones (arrows).
Fig. 3 Serial MRI scans of 45 years old woman with early RA. (A) Baseline coronal T1W MR image scan of the wrist shows low signal
in the trapezium and scaphoid bones reﬂecting bone marrow edema. (B) Baseline contrast enhanced image shows marked synovial
enhancement. (C) At 18 months, there is marked reduction of enhancement with appearance of two new erosions in trapezium and
scaphoid.
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MRI parameters, clinical and laboratory measures and medi-
cations at baseline and 18 month follow up are presented in
Table 1. The erosion score progressed signiﬁcantly, while clin-
ical and laboratory measures improved signiﬁcantly from base-
line to 18 months follow up period. Regarding sharp score
there was non-signiﬁcant progression from baseline to
18 months.
A persistent response to the treatment was found in 20
patients out of 48 (41%), while inadequate response in 28(59%) throughout 18 months of follow up. There was a signif-
icant difference between responders and non-responders
regarding MRI data (Table 2) while, non-signiﬁcant differ-
ences regarding clinical and laboratory ﬁndings, age, sex and
medication were found between these groups (data not
shown). Furthermore in the group of non-responders, 18
patients out of 28 (64%) presented new/progressive erosions,
while 10 (36%) had stopped erosive progression. We also
found that patients who presented with erosive progression
from baseline to 18 months had highly signiﬁcant MRI synovi-
tis scores, edema scores and E-rate, while had non-signiﬁcant
Fig. 4 MRI scans of 51 years old woman with early RA and normal X-ray ﬁnding at presentation. (A) Baseline coronal fat suppressed
T2 weighted image shows diffuse bone marrow edema with high signal intensity in carpal bones and base of second metacarpal bone. (B)
At 18 months follow up, bone edema subsides with appearance of bone erosions at sites of previous marrow edema.
Table 2 Comparison between clinical responders and non responders regarding MRI data from baseline to 18 months.
MRI Data Responders n= 20 (41%) Non responders n= 28(59%) P
Erosion score 3(0.1–0.7) 8(4–10) <0.05
Synovitis score 2.5(1.5–3.5) 5(2.5–7.5) <0.05
Edema score 1.5(1–2.5) 6(2–9) <0.05
E rate 1.9(0.9–2.8) 3.2(1.2–4.9) <0.05
Table 3 Parameters of clinical non responders regarding erosion progression at 18 months follow up period.
Without (n= 10) (36%) With (n= 18) (64%) P
MRI data
Erosion score 3(1.1–7.1) 7(4–8) <0.05
Synovitis score 4(2–4) 7(6–9.1) <0.05
Edema score 2(0–2.1) 6(1.9–9.1) <0.05
E-rate 1.3(0.9–3.2) 2.9(2.1–4.8) <0.05
Clinical measures
Swollen joint count 8(4–16) 11(6–20) >0.05
Tender joint 10(6–18) 13(8–22) >0.05
DAS score 4.8(2.5–6.1) 5.6(2.9–6.8) >0.05
HAQ score 1(0,6–1.8) 1,5(0,8–3) >0.05
ESR 29(10–131) 32(20–40) >0.05
CRP 12(4–22) 15(7–25) >0.05
Pain score 30(18–42) 45(12–55) >0.05
Modiﬁed sharp score 75(45–94) 86(67–96) >0.05
Dynamic contrast enhanced MRI of wrist 807difference regarding clinical measures and sharp score than
non-responders without progressive bone damage (Table 3).
Erosive development on MRI correlated signiﬁcantly
(P< 0.05) with the baseline bone edema score, synovitis score,
E-rate, pain score, and ESR, while age, sex, medication use
(presence of DMARDs or prednisone at baseline), swollen or
tender joint count, DAS score, sharp score, and HAQ score
did not correlate with changes in the bone erosion score from
baseline to 18 months (Table 4). Regarding E-rate it was cor-
related signiﬁcantly with all MRI parameters at baseline, but
did not correlate with sharp score and clinical and laboratory
measures except for ESR and pain score (Table 5). In multivar-
iate logistic regression analysis, bone marrow edema was
found to be the only variable that predicts bone erosion later
on (Table 6).5. Discussion
Imaging techniques have played an important role in assessing
disease progression and response to treatment in rheumatoid
arthritis (RA) for many years. Plain X-rays have been widely
used together with scoring systems designed to quantify disease
and measure progression and response to treatment. However,
these rely on relatively late disease features such as bone ero-
sions and joint space narrowing (10) hence the use of advanced
imaging modalities has allowed greater understanding of the
rheumatoid arthritis (RA) disease process and the links
between inﬂammation and damage (11).
MRI is the only tool to provide the possibility of studying
BME, which is true inﬂammatory osteitis (12,13) so, it was
chosen as the outcome measure of this study. Many studies
Table 4 Correlation between erosion score and baseline
variables at 18 months.
Variables R P
MRI data
Edema score 0.77 <0.05
Synovitis score 0.58 <0.05
E-rate 0.48 <0.05
Clinical ﬁndings
Swollen joint count 0.22 >0.05
DAS 0.22 >0.05
Tender joint count 0.18 >0.05
HAQ 0.25 >0.05
ESR 0.59 <0.05
CRP 0.27 >0.05
Pain score 0.38 <0.05
Modiﬁed sharp score 0.19 >0.05
Table 5 Correlation between E-rate and baseline variables at
18 months.
Variables R P
Edema score 0.75 <0.05
Erosion score 0.66 <0.05
Synovitis score 0.58 <0.05
Swollen joint count 0.18 >0.05
Tender joint count 0.29 >0.05
DAS score 0.21 >0.05
HAQ score 0.25 >0.05
ESR 0.59 <0.05
CRP 0.24 >0.05
Pain score 0.39 <0.05
Modiﬁed sharp score 0.23 >0.05
Table 6 Multivariate logistic regression analysis of baseline
variables associated with changes in bone erosion.
Variables OR 95% CI
-Bone edema 28 (11.7–67.1)
-E-rate 12 (4.1–29.2)
-Static synovitis 14.9 (6.3–34.9)
-ESR 10.3 (6–27.1)
-Pain score 9.9 (5.5–25)
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including joint swelling, pain (14) disease activity score
(DAS), HAQ (15), erosion progression (6) and response to
treatment (16). In contrast, Reiser et al. did not ﬁnd any cor-
relation between E-rate and clinical activity (17). The picture
with ESR is more confused with some studies ﬁnding a corre-
lation (1,18), while others were unable to do so (7). Two stud-
ies have compared DCE-MRI with progression of bone
erosion (deﬁned by OMERACT score) and have demonstrated
a correlation between E-rate and erosive progression after
1 year (42 patients) (18) and 2 years (24 patients) (6). This pro-
vides that DCE-MRI predicts erosive progression.
In our study we did not ﬁnd any correlation between E-rate
and clinical and laboratory measures except for ESR and pain
score while there was a signiﬁcant correlation between E-rate
and all MRI parameters at 18 months follow up.Although conventional radiography has been considered as
the golden standard for the assessment of joint damage in RA,
MRI has been shown to have higher sensitivity in the monitor-
ing of erosive progression (6). In an established RA follow-up
study, 78% of the new radiographic erosions could be visual-
ized 2 years earlier by MRI than by conventional radiography.
Longitudinal studies have demonstrated the relationship
between MRI-detectable inﬂammation, bone edema and sub-
sequent MRI-detectable bone damage, Mc Queen (19) and
Hetland (20) reported that baseline edema score was the only
MRI feature on multivariate analysis to predict 6 and 2 year
sharp score, respectively while baseline synovitis score did
not predict changes in sharp score (19,20,23). Moreover Oster-
guard (21) concluded that MRI erosive progression at
3 months correlates with X-ray progression at 9 months, these
ﬁndings are more or less in accordance with our results where
we found no correlation between MRI erosion score and X-ray
progression (modiﬁed Sharp score) during follow up period.
On the other hand, Bird et al. (22) concluded that there was
no clear beneﬁt of MRI over X-ray.
In this study, non-signiﬁcant improvements in imaging
synovitis and osteitis were concordant with signiﬁcant reduc-
tions in clinical and laboratory measures, as would be
expected. This is consistent with the ﬁndings of other studies
which have also reported MRI to be more sensitive for detect-
ing synovitis than clinical assessment (24), in addition
Molenaar et al. reported that clinically relevant progression
of joint damage does sometimes occur in patients in
prolonged clinical remission where there is minimal if any
clinical synovitis (25).
This could also be concluded from the ﬁndings documented
here, as patients clinically responding to treatment had resid-
ual imaging synovitis at 18 months despite responding clini-
cally to DMARD therapy. Brown et al. also reported that
imaging synovitis occurred frequently in patients with RA
who fulﬁlled the clinical criteria for remission (26) suggesting
a ‘ﬂoor effect’ for the clinical detection of joint inﬂammation
below which subclinical inﬂammation can only be revealed
by imaging, concerning the ability of MRI to act as a tool
for monitoring change in synovitis or osteitis. A proof of con-
cept of the tight relationship between clinically active joints
and structural changes is provided by the demonstration that
repair (the opposite of progression), although it remains an
extremely rare feature in RA (27), may only occur in associa-
tion with improvement or cessation of clinical swelling (28).
The crucial importance of joint assessment to predict radio-
graphic outcomes in patients with RA is further highlighted by
recent evidences showing that joint damage progression in
remission is driven by residual swollen joints (29), which
appear to be more predictive compared with other variables
of inﬂammation such as acute phase reactants (30). This ﬁnd-
ing accentuates the importance of early aggressive treatment of
MRI-detected inﬂammation, with the target of reducing the
total load of MRI inﬂammation over time in order to reduce
bone destruction and improve patient outcome. The results
of the present study indicate that patients at high-risk for ero-
sive progression on wrist MRI have high local inﬂammatory
activity at baseline, which can be reliably detected in
contrast-enhanced dynamic and static MRI. Furthermore, at
follow-up, active erosive disease can be detected with this
method. Our results support the existing data on the impor-
tance of MRI in disease monitoring and the prognostication
Dynamic contrast enhanced MRI of wrist 809of erosive disease. This study and several others
(11,19,20,24,26) clearly show that osteitis in the subchondral
bone is far more predictive of the later development of bone
erosion than is synovitis. It can be hypothesized that the devel-
opment and progression of erosions would be most closely
associated with osteitis (MRI bone edema), but there would
also be a weaker association with synovitis (as both synovitis
and osteitis are sponsored by the same underlying process (11).
Only in the study reported by Brown et al. MRI bone
edema has been found to be less predictive of radiographic ero-
sions than MRI synovitis (31). Interestingly, that group did
not use T2-weighted or STIR sequences in their MRI protocol
for the detection of bone edema, as recommended by the Out-
come Measures in Rheumatology Clinical Trials (OME-
RACT) Rheumatoid Arthritis Magnetic Resonance Imaging
Scoring (RAMRIS) system (32).
There is no doubt that synovial inﬂammation, osteitis and
bone erosion are all intimately connected. However, much evi-
dence exists to suggest that osteitis is more strongly predictive
of bone erosion than synovitis, supporting the notion that
there is a more direct connection between bone inﬂammation
and bone damage than between synovial inﬂammation and
bone damage. Synovitis and osteitis might be viewed as cous-
ins with a common ancestor, the process that ultimately drives
both remaining obscure but quite possibly sited in the bone
marrow. However, the reduction of both synovitis and osteitis
is clearly an important therapeutic goal. The detection and
monitoring of synovitis are often more feasible in clinical prac-
tice using US than MRI scanning, but the latter does afford
the opportunity to detect and monitor bone edema at the same
time (11).6. Conclusion
Dynamic contrast enhanced MRI produces sensitive informa-
tion regarding synovitis score (1–3) in early RA. Furthermore,
it is the only tool that provides the possibility of studying bone
marrow edema which is the strongest predictor of subsequent
bone erosion in early RA patients. Hence we can conclude that
MRI has a diagnostic and prognostic value in predicting early
RA patients at high risk of erosion development later on.Conﬂict of interest
None.
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